Kosek, Jolanta

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 203

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

Hoffmann, M., Kasserra, C., Reyes, J., Schafer, P., Kosek, J., Capone, L., Parton, A., Kim-Kang, H., Surapaneni, S., & Kumar, G. (2013) · Cancer Chemotherapy and Pharmacology

Pharmacogenetics and Drug MetabolismProtein Degradation and Inhibitors

Cited by 121

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

Schafer, P. H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M., & Chopra, R. (2018) · Annals of the Rheumatic Diseases

Systemic Lupus Erythematosus ResearchProtein Degradation and Inhibitors

Cited by 78